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standard, and setting a cut-off scores of 20 for the DMI-18, >8
for the HADS, >5 for the PHQ-9, and >4 for the BDI-FS to
diagnose depression. CONCLUSIONS: The Spanish validated
DMI-18 scale maintains an adequate conceptual and semantic
equivalence with the original and is easily understood by
patients. It also has shown adequate sensitivity and speciﬁcity in
the detection of affective disorders with similar results to those of
the original version (sensitivity 91.7%–95.0%, speciﬁcity
68.1%–72.4%). Its sensitivity to detect depression is compara-
tively lower than the sensitivity of the convergent measures, but
its speciﬁcity if notably better.
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BACKGROUND: Patient centered care requires physicians to
accommodate views and needs of patients, but to date there has
been little evidence as to the degree of concordance between
patients and physicians in terms of their treatment goals and its
achievement. OBJECTIVES: To identify, value and compare the
treatment goals of patients and physicians for the treatment of
schizophrenia, and to measure self reported and physician per-
formance of patients with respect to these goals. METHODS: A
mixed methods approach was taken combining qualitative and
quantitative data. First, 20 relevant treatment goals were iden-
tiﬁed through patient focus groups (n = 30) and literature. A
survey was then developed to rank the goals and to rate its
importance using 5-point Likert scales. Finally degree of
achievement was assessed. The survey was administered to both
patients (n = 105) and physicians (n = 160) by trained ﬁeld
workers. Data was analyzed using means and t-tests as appro-
priate. RESULTS: We found that the three most important goals
for patients were: reduction of anxiety (80.5), improvement of
cognitive abilities (79.25), and reduced feelings of depression
(79). Physicians rated: reduction of symptoms (82.25), increase
of self-conﬁdence (80.75), and improvement of cognitive abili-
ties (80.5) as having the highest importance. When asked to rate
the performance of patients with respect to these goals, we
found that physicians continuously judged more critical than
patients. Signiﬁcant differences were found for improvement of
cognitive abilities (p < 0.05), increase of independence (p <
0.05), decrease lack of emotion (p < 0.05), increase of overall-
satisfaction (p < 0.05), improved ability to express oneself (p <
0.05), and recreation of social contacts (p < 0.05). CONCLU-
SIONS: Results suggest that schizophrenic patients and physi-
cians value treatment goals and their achievement relative
discordant. As schizophrenic patients are capable to state their
requirements, this should be considered in treatment decisions
to improve treatment outcomes.
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OBJECTIVES: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less
extend. Aim of this study therefore was to explore the patients
perceptions of an “ideal treatment” for ADHD. METHODS:
Examination of the state of the art as reported in the literature
was followed by a qualitative study with four focus groups
consisting of 6–8 parents of ADHD-patients each. In a subse-
quent quantitative study phase, data was collected in an online or
paper-pencil self-ﬁll-in questionnaire for parents of patients and
patient (age >14 years) themselves. It included sociodemographic
data, treatment history and actual treatment and patients pref-
erences of therapy characteristics using direct measurement (23
items on a 5-point Likert-scale) as well as a discrete-choice-
experiment (DCE, 8 pairs with 6 characteristics). RESULTS: N =
213 questionnaires were ﬁlled; most of them by the parents of
patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results. CONCLUSIONS:
N = 213 questionnaires were ﬁlled; most of them by the parents
of patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results.
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OBJECTIVES: Traditionally, unmet needs are assessed using
claims data, clinician-reported metrics, or patient-reported
metrics from clinical trials. We seek to use patient-reported
survey data from ﬁve European countries to quantify unmet
needs of patients with depression currently using selective sero-
tonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs). This study will highlight the beneﬁts
of patient-reported survey data. METHODS: We analyzed data
from the 2007 European National Health and Wellness Survey,
an annual, cross-sectional, patient-reported survey of adults
(aged 18+) in France, Germany, Italy, Spain, and the UK. The
sample for analysis consisted of patients with diagnosed depres-
sion currently using an SSRI or SNRI and excluded patients with
bipolar disorder. Unmet needs were deﬁned as an afﬁrmative
response to the following symptoms in the past month: bothered
by feeling down, depressed or hopeless; and bothered by having
little interest or pleasure in doing things. Survey data were pro-
jected to national populations. Chi-square was used to test for
differences across countries. RESULTS: We found 1630 SSRI and
355 SNRI users in the sample, projecting to 6.93 and 1.46
million, respectively. There were 82.5% of SSRI users and 84.3%
of SNRI users who were bothered by feeling down, depressed, or
hopeless, equating to 5.71 and 1.23 million, respectively. Simi-
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